Formalin-fixed, paraffin-embedded (FFPE) tissues are a vast and invaluable source of information for disease research, particularly in the field of cancer. Due to fixation and storage processes, RNA obtained from FFPE samples can suffer from high levels of degradation, resulting in unreliable and inaccurate gene expression profiles and higher sequencing depth requirements. To overcome these challenges, TruSeq Exome RNA sequencing was developed. The benefits of TruSeq Exome RNA sequencing include the ability to generate robust gene expression profiles using RNA from FFPE and low-quality samples. In addition, TruSeq Exome RNA sequencing requires less RNA and less sequencing depth than standard mRNA sequencing, thus enabling more cost-effective transcriptome analysis. Novogene’s clinical TruSeq Exome RNA sequencing is ensured by streamlined and standardised protocols, as well as strict quality controls throughout the workflow.
Advantages of Clinical TruSeq Exome RNA Sequencing with Novogene
Quality management
System that meets the requirements of national and international standards, including CAP accreditation
High value
Higher performance than standard polyA enrichment mRNA sequencing, with higher Q30 values, lower rRNA%, and higher percentage of clean reads.
High quality
Data covering gene expression quantification, differential expression and enrichment analysis, and various advanced analysis options
Bioinformatics expertise
Publication-ready results and bioinformatic consultants available for data interpretation
Clinical TruSeq Exome RNA Sequencing Highlights
- High-quality data from challenging samples, including FFPE samples, with low input
- CAP-compliant TruSeq RNA exome sequencing
- Publication-ready results and bioinformatics experts available to interpret the data
Sample Requirements
| Sample Type | Amount | Volume | Concentration | Description | Collection Tube Recommended |
|---|---|---|---|---|---|
| Total RNA | ≥ 200 ng | ≥ 20 µl | ≥ 20 ng/µl | • OD260/280 > 2.0 • No degradation • No DNA contamination • Fragments should be longer than 500nt |
1.5 ml or 2 ml microcentrifuge tube |
Data Quality Metrics
| Sample ID | Total Exonic Mapping Rate (%) |
Clean Data (%) |
Error Rate (%) |
Q30 (%) |
rDNA (%) |
|---|---|---|---|---|---|
| 1 | 86.01 | 99.61 | 0.02 | 95.16 | 0.09 |
| 2 | 85.55 | 99.33 | 0.02 | 94.6 | 0.13 |
| 3 | 85.45 | 99.25 | 0.02 | 94.24 | 0.15 |
| 4 | 85.32 | 99.48 | 0.02 | 94.53 | 0.03 |
| 5 | 85.06 | 96.94 | 0.02 | 96.78 | 0.06 |
| 5 | 85.06 | 96.94 | 0.02 | 96.78 | 0.06 |
| 6 | 84.76 | 96.56 | 0.02 | 96.84 | 0.03 |
| 7 | 84.76 | 99.35 | 0.02 | 95.01 | 0.09 |
| 8 | 84.74 | 99.34 | 0.02 | 94.81 | 0.05 |
| 9 | 84.16 | 96.61 | 0.02 | 96.84 | 0.07 |
| 10 | 84.09 | 96.62 | 0.02 | 96.88 | 0.03 |
